Xiamen Innovax Biotech Co., Ltd.

As one of the leading vaccine manufacturers in China, Xiamen Innovax Biotech Co., Ltd. (Innovax) was founded in 2005 and has been dedicated to human vaccine development, manufacturing and commercialization for nearly 20 years. As a wholly owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Wantai BioPharm), a public listed company in China (Stock Code: 603392), Innovax’s mission is to provide high-quality and affordable vaccines to improve human well-being.

Innovax has developed a unique recombinant virus-like particle (VLP) vaccine platform based on Escherichia coli, leveraging this cutting-edge technology to successfully launched the world’s first recombinant hepatitis E vaccine (Hecolin) and the world’s second HPV bivalent vaccine (Cecolin). In 2025, Innovax’s HPV 9-valent vaccine (Cecolin 9) has just been approved in China, which is the world’s second Nine-valent Human Papillomavirus Vaccine. Innovax never stops advancing in innovation for life.